Charles River Laboratories International, Inc. CRL
- Market cap
- $14.1B
- P/E
- 0.0×
Follow CRL
Charles River Laboratories International, Inc. (CRL) Total debt
Charles River Laboratories International, Inc.'s total debt at the end of fiscal 2025 was $2.1B, unchanged from fiscal 2024. At the end of the quarter to 30 June 2026 it was $2.6B. Over the past ten years it has ranged from $863.0M (fiscal 2015) to $2.8B (fiscal 2022); the current reading is higher than 64% of that period. Charles River Laboratories International, Inc. ranks 10th of 50 Diagnostics & Research companies by total debt.
Total debt, annual
Annual
| Period | Total debt | Change |
|---|---|---|
| FY2025 | $2.1B | (4.64%) |
| FY2024 | $2.2B | (15.37%) |
| FY2023 | $2.6B | (4.00%) |
| FY2022 | $2.8B | 2.15% |
| FY2021 | $2.7B | 36.36% |
| FY2020 | $2.0B | 4.85% |
| FY2019 | $1.9B | 13.20% |
| FY2018 | $1.7B | 45.66% |
| FY2017 | $1.1B | (7.28%) |
| FY2016 | $1.2B | 43.10% |
Quarterly
| Period | Total debt | Change |
|---|---|---|
| Jun 2026 | $2.6B | (1.62%) |
| Mar 2026 | $2.7B | 24.66% |
| Dec 2025 | $2.1B | (2.25%) |
| Sep 2025 | $2.2B | (6.30%) |
| 42 more quarters | Free account |
Against its own ten years
Total debt against peers
| Company | Total debt |
|---|---|
| LH Labcorp Holdings Inc. compare | $5.9B |
| DGX Quest Diagnostics Incorporated compare | $5.6B |
| ICLR ICON PLC compare | $3.4B |
| RVTY Revvity Inc. compare | $3.2B |
| CRL Charles River Laboratories International, Inc. | $2.6B |
| QGEN QIAGEN N.V. compare | $1.6B |
| GH Guardant Health, Inc. compare | $1.5B |
| MEDP Medpace Holdings, Inc. compare | $163.0M |
| TWST Twist Bioscience Corporation compare | $15.0M |
What Total debt is
Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.
Long Term Debt (Total) + Current Part of Debt
More on CRL
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement